Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep;15(9):294.
doi: 10.1007/s13205-025-04470-8. Epub 2025 Aug 13.

Clinical insights into catechin-based nanomedicine: a review of therapeutic potential in neurodegenerative diseases

Md Al Amin #  1 , Mehrukh Zehravi #  2 , Sherouk Hussein Sweilam  3   4 , Thukani Sathanantham Shanmugarajan  5 , Uppuluri Varuna Naga Venkata Arjun  5 , Mogan Babu Nagaiyan  6 , S Mounika Reddy  7 , Vijayakumar Subash  8 , Kalam Mary Swarnalatha  5 , Arjun Pazhanikumar  5 , Joel Mart  9 , P Dharani Prasad  10 , Mohammad Idreesh Khan  11 , Irfan Ahmad  12 , Talha Bin Emran  1
Affiliations
Review

Clinical insights into catechin-based nanomedicine: a review of therapeutic potential in neurodegenerative diseases

Md Al Amin et al. 3 Biotech. 2025 Sep.

Abstract

Neurodegenerative diseases (NDs) such as Alzheimer's, Parkinson's, and Huntington's diseases are characterized by progressive neuronal loss, oxidative stress, neuroinflammation, and cognitive decline. The most prevalent and bioactive catechin in green tea, epigallocatechin-3-gallate (EGCG), has shown promise as a neuroprotective agent because of its many biological properties. The review discusses the potential of EGCG in combating neurodegeneration and cognitive impairments through antioxidant benefits and signaling pathways. Recent advancements in structural analogs, liposomal encapsulation, and nanoformulations have shown potential in improving pharmacokinetics. High dosage safety issues and inter-individual response variability remain significant challenges in the field of medicine. The review emphasizes the importance of structured clinical trials, formulation uniformity, biomarker-guided monitoring, and customized therapy approaches to fully realize EGCG's potential as a neuroprotective drug. EGCG improves autophagic clearance, reduces tau hyperphosphorylation, and inhibits amyloid-beta aggregation, aiding in neuroprotective properties. Early clinical trials suggest it can be used as an adjuvant therapy, and recent advancements in formulation and delivery techniques are promising.

Keywords: Cognitive impairments; Epigallocatechin-3-gallate; Neurodegenerative diseases; Neuroprotection; Oxidative stress.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestThe authors declare no conflict of interest.

References

    1. Abubakar M et al (2025) Diabetes, alzheimer’s disease risk factors, and the cafeteria diet: a comprehensive review. Curr Neuropharmacol. 10.2174/011570159X384737250626094315 - PubMed
    1. Ahmad N, Mukhtar H (1999) Green tea polyphenols and cancer: biologic mechanisms and practical implications. Nutr Rev 57(3):78–83 - PubMed
    1. Ahmed R, VanSchouwen B, Jafari N, Ni X, Ortega J, Melacini G (2017) Molecular mechanism for the (−)-epigallocatechin gallate-induced toxic to nontoxic remodeling of Aβ oligomers. J Am Chem Soc 139(39):13720–13734 - PubMed
    1. Aktas O et al (2004) Green tea epigallocatechin-3-gallate mediates T cellular NF-κB inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol 173(9):5794–5800 - PubMed
    1. Ali B et al (2016) In silico analysis of green tea polyphenols as inhibitors of AChE and BChE enzymes in Alzheimer’s disease treatment. CNS Neurol Disord Drug Targets Form Curr Drug Targets-CNS Neurol Disorders 15(5):624–628 - PubMed

LinkOut - more resources